RNAZ – transcode therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
Form 10-Q Transcode Therapeutics, For: Sep 30
Form SCHEDULE 13G/A Transcode Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Form SCHEDULE 13D/A Transcode Therapeutics, Filed by: CK Life Sciences Intl (Holdings) Inc
Form DEFA14A Transcode Therapeutics,
Form 8-K Transcode Therapeutics, For: Oct 27
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.